Study of in vitro glucuronidation of hydroxyquinolines with bovine liver microsomes

被引:22
作者
Kanou, M [1 ]
Saeki, K [1 ]
Kato, TA [1 ]
Takahashi, K [1 ]
Mizutani, T [1 ]
机构
[1] Nagoya City Univ, Dept Drug Metab & Disposit, Grad Sch Pharmaceut Sci, Nagoya, Aichi 4678603, Japan
关键词
fluoroquinoline; hydroxyquinoline; microsomes; quinoline; UDP-glucuronosyltransferase (UGT);
D O I
10.1046/j.1472-8206.2002.00097.x
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Glucuronidation of drugs by UDP-glucuronosyltransferase (UGT) is a major phase II conjugation reaction. Defects in UGT are associated with Crigler-Najjar syndrome and Gilbert's syndrome with severe hyperbilirubinaemias and jaundice. We analysed the reactivities of some hydroxyquinoline derivatives, which are naturally produced from quinoline by cytochrome P450. The analyses were carried out using a microassay system for UGT activity in bovine liver microsomes in the range 0.5-100 pmol/assay with the highly sensitive radio-image analyser Fuji BAS2500 (Fujifilm, Tokyo, Japan). 3-Hydroxylquinoline is a good substrate for glucuronidation, and the relative K-cat values were 3.1-fold higher than the values for p-nitrophenol. 5,6-Dihydroquinoline-5,6-trans-diol gave a similar K-m value to that of 3-hydroxy-quinoline, but the V-max value was approximately 1/15 of that of p-nitrophenol and showed weak reactivity. Quinoline N-oxide gave a low V-max value and showed marginal activity. The K-cat values of 6-hydroxyquinoline and 5-hydroxyquinoline were 2.1- and 1.2-fold higher than that of p-nitrophenol, respectively. Fluoroquinoline (FQ) derivatives, such as 3FQ, 7,8diFQ and 6,7,8triFQ, did not show any substrate activities. These results suggest that there are therapeutic problems in administration of some quinoline drugs to patients with jaundice.
引用
收藏
页码:513 / 517
页数:5
相关论文
共 17 条
[1]
SYNTHESIS OF ARENE OXIDE AND TRANS-DIHYDRODIOL METABOLITES OF QUINOLINE [J].
AGARWAL, SK ;
BOYD, DR ;
DAVIES, RJH ;
HAMILTON, L ;
JERINA, DM ;
MCCULLOUGH, JJ ;
PORTER, HP .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 1990, (07) :1969-1974
[2]
ANALYSIS OF GENES FOR BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE IN GILBERTS-SYNDROME [J].
AONO, S ;
ADACHI, Y ;
UYAMA, E ;
YAMADA, Y ;
KEINO, H ;
NANNO, T ;
KOIWAI, O ;
SATO, H .
LANCET, 1995, 345 (8955) :958-959
[3]
Functions and transcriptional regulation of PAH-inducible human UDP-glucuronosyltransferases [J].
Bock, KW ;
Gschaidmeier, H ;
Heel, H ;
Lehmköster, T ;
Münzel, PA ;
Bock-Hennig, BS .
DRUG METABOLISM REVIEWS, 1999, 31 (02) :411-422
[4]
FUNCTION AND REGULATION OF UDP-GLUCURONOSYLTRANSFERASE GENES IN HEALTH AND LIVER-DISEASE - REPORT OF THE 7TH INTERNATIONAL WORKSHOP ON GLUCURONIDATION, SEPTEMBER-1993, PITLOCHRY, SCOTLAND [J].
BURCHELL, B ;
COUGHTRIE, MWH ;
JANSEN, PLM .
HEPATOLOGY, 1994, 20 (06) :1622-1630
[5]
Effects of oligofluorine substitution on the mutagenicity of quinoline: a study with twelve fluoroquinoline derivatives [J].
Kato, T ;
Saeki, K ;
Kawazoe, Y ;
Hakura, A .
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 1999, 439 (02) :149-157
[6]
Anti-mutagenic structural modification by fluorine-substitution in highly mutagenic 4-methylquinoline derivatives [J].
Kato, T ;
Hakura, A ;
Mizutani, T ;
Saeki, K .
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2000, 465 (1-2) :173-182
[7]
The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence [J].
Mackenzie, PI ;
Owens, IS ;
Burchell, B ;
Bock, KW ;
Bairoch, A ;
Belanger, A ;
FournelGigleux, S ;
Green, M ;
Hum, DW ;
Iyanagi, T ;
Lancet, D ;
Louisot, P ;
Magdalou, J ;
Chowdhury, JR ;
Ritter, JK ;
Schachter, H ;
Tephly, TR ;
Tipton, KF ;
Nebert, DW .
PHARMACOGENETICS, 1997, 7 (04) :255-269
[8]
Drug glucuronidation by human renal UDP-glucuronosyltransferases [J].
McGurk, KA ;
Brierley, CH ;
Burchell, B .
BIOCHEMICAL PHARMACOLOGY, 1998, 55 (07) :1005-1012
[9]
PURIFICATION AND PROPERTIES OF BOVINE LIVER SERYL-TRANSFER RNA-SYNTHETASE [J].
MIZUTANI, T ;
NARIHARA, T ;
HASHIMOTO, A .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1984, 143 (01) :9-13
[10]
Murata M, 1998, DRUG METAB DISPOS, V26, P1113